Live feed08:00:00·1270dPRReleasevia QuantisnowVertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaByQuantisnow·Wall Street's wire, on your screen.CRSP· CRISPR Therapeutics AGVRTX· Vertex Pharmaceuticals IncorporatedHealth Care
